[EN] HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES D'EGFR DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
申请人:BLUEPRINT MEDICINES CORP
公开号:WO2022271749A1
公开(公告)日:2022-12-29
The present disclosure provides a compound represented by structural formula (I):or a pharmaceutically acceptable salt thereof useful for treating a cancer.
本公开提供一种化合物,其结构式表示为(I):或其药学上可接受的盐,用于治疗癌症。
Rearrangements and cyclizations—XVI
作者:Nikolai S. Zefirov、Sergei I. Kozhushkov、Tamara S. Kuznetsova
DOI:10.1016/0040-4020(82)80149-x
日期:1982.1
hydroxylamine derivatives proceed via cyclopropane ring opening with incorporation of external nucleophile (solvent) to give the 4-β-X-ethyl derivatives of 3,5-dimethylpyrazoles and -isoxazoles, a novel route to these heterocycles. This ring cleavage occurs especially smoothly in water as a solvent. A rationale for this unusually mild nucleophilic cyclopropane ring opening is discussed.